HC Wainwright Initiates Coverage on Urovant Sciences (UROV)

Share on StockTwits

HC Wainwright started coverage on shares of Urovant Sciences (NASDAQ:UROV) in a report issued on Monday, MarketBeat.com reports. The firm issued a buy rating and a $28.00 price target on the stock.

Separately, Zacks Investment Research upgraded shares of Urovant Sciences from a hold rating to a buy rating and set a $4.75 price target for the company in a research report on Tuesday, December 25th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of Buy and a consensus target price of $19.55.

NASDAQ UROV opened at $13.60 on Monday. Urovant Sciences has a 1-year low of $4.05 and a 1-year high of $14.32.

Urovant Sciences (NASDAQ:UROV) last released its quarterly earnings results on Wednesday, February 13th. The company reported ($0.87) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.09) by $0.22. On average, equities analysts expect that Urovant Sciences will post -4.21 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Asymmetry Capital Management L.P. bought a new position in Urovant Sciences in the third quarter valued at approximately $1,902,000. BlackRock Inc. bought a new position in Urovant Sciences in the third quarter valued at approximately $4,574,000. FMR LLC bought a new position in Urovant Sciences in the third quarter valued at approximately $14,400,000. Dean Capital Investments Management LLC bought a new position in Urovant Sciences in the third quarter valued at approximately $618,000. Finally, Monashee Investment Management LLC bought a new position in Urovant Sciences in the third quarter valued at approximately $630,000. Institutional investors own 21.84% of the company’s stock.

Urovant Sciences Company Profile

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions. It is developing vibegron, an oral, once-daily, small molecule beta-3 agonist that is in Phase III trials for the treatment of overactive bladder (OAB) and OAB in men with benign prostatic hyperplasia; and in Phase IIa clinical trials for irritable bowel syndrome-associated pain.

Read More: What are catch-up contributions?

Receive News & Ratings for Urovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Urovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

SPDR Portfolio Small Cap ETF  Stake Lessened by Asset Dedication LLC
SPDR Portfolio Small Cap ETF Stake Lessened by Asset Dedication LLC
Vermont utility Needs renewable power that is 100% by 2030
Vermont utility Needs renewable power that is 100% by 2030
Asset Dedication LLC Purchases 116 Shares of Adobe Inc
Asset Dedication LLC Purchases 116 Shares of Adobe Inc
American Century Companies Inc. Has $267,000 Stake in CoreSite Realty Corp
American Century Companies Inc. Has $267,000 Stake in CoreSite Realty Corp
American Century Companies Inc. Sells 1,516,500 Shares of Iamgold Corp
American Century Companies Inc. Sells 1,516,500 Shares of Iamgold Corp
iShares MSCI ACWI ETF  Position Lifted by American Century Companies Inc.
iShares MSCI ACWI ETF Position Lifted by American Century Companies Inc.


 
© 2006-2019 Zolmax.